Floatz logo

Mifomelatide

Pancreatic Ductal Adenocarcinoma (mPDAC)

protein_peptideDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

283 Active assets in the Pancreatic Ductal Adenocarcinoma (mPDAC) cohort.

Asset / SponsorPhaseRating
Irinotecan
NRG Oncology
Phase 3BB
Daraxonrasib
Revolution Medicines, Inc.
Phase 3BB
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
OHSU Knight Cancer Institute
Phase 2BB
Rmc-6236
Tango Therapeutics, Inc.
Phase 3BB
S-1
Genentech, Inc.
Phase 2BB

View all 50 →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →